Terlipressin and albumin
PreclinicalSmall molecule
Terlipressin and albumin is one of 15 small molecule programs targeting Hepatorenal Syndrome. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
25 competitors in Hepatorenal Syndrome
#DrugCompanyPhaseTrials
1Glypressin
MMallinckrodt
Approved
Levophed
GGeneral Hospital of Ningxia Medical University
Phase 3
Proamatine
TakedaPhase 2
Letairis
GileadPhase 2
Noradrenaline
IInstitute of Liver and Biliary Sciences, India
Phase 3
Giapreza
LLa Jolla Pharmaceutical Company
Phase 2
NORADRENALIN
UUniversity of Aarhus
Phase 3
Albumin
LLaboratoire français de Fractionnement et de Biotechnologies
Phase 2
Ifetroban
CCumberland Pharmaceuticals
Phase 2
Terlipressin Plus Albumin
UUniversity of Padova
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Terlipressin and albumin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- HHospital Clinic of Barcelona